1. Home
  2. ITOC vs REVB Comparison

ITOC vs REVB Comparison

Compare ITOC & REVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

ITOC

iTonic Holdings Ltd Class A Ordinary Shares

N/A

Current Price

$0.30

Market Cap

4.9M

Sector

N/A

ML Signal

N/A

Logo Revelation Biosciences Inc.

REVB

Revelation Biosciences Inc.

HOLD

Current Price

$1.10

Market Cap

4.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ITOC
REVB
Founded
1998
2020
Country
China
United States
Employees
7
9
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.9M
4.2M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
ITOC
REVB
Price
$0.30
$1.10
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
67.0K
55.8K
Earning Date
03-20-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.25
$0.47
52 Week High
$0.65
$3.21

Technical Indicators

Market Signals
Indicator
ITOC
REVB
Relative Strength Index (RSI) 43.64 52.15
Support Level $0.28 $1.06
Resistance Level $0.34 $1.20
Average True Range (ATR) 0.03 0.06
MACD -0.00 0.01
Stochastic Oscillator 33.33 95.74

Price Performance

Historical Comparison
ITOC
REVB

About ITOC iTonic Holdings Ltd Class A Ordinary Shares

iTonic Holdings Ltd through its subsidiary, focuses on healthcare solutions for brachytherapy, a targeted radiation therapy used in cancer treatment. Its product, Beijing Feitian's Treatment Planning System, helps ensure safe and effective brachytherapy using radioactive sources inside the patient to kill cancer cells and shrink tumors. Its product portfolio also includes Medical Auxiliary Supplies such as seed implant needles, computer workstations, patient positioning device, etc.

About REVB Revelation Biosciences Inc.

Revelation Biosciences Inc is a clinical-stage life science company focused on rebalancing inflammation to optimize health using its proprietary formulation, Gemini. The company is developing a pipeline of potential products based on Gemini, which is its proprietary formulation of phosphorylated hexaacyl disaccharide (PHAD), a synthetic version of monophosphoryl lipid A (MPLA). PHAD is a small fragment of lipopolysaccharide (LPS) that stimulates TLR4 and leads to controlled production of multiple cytokines and chemokines that modulate the innate and adaptive immune response. The company operates through one reportable segment focused on the prevention and treatment of disease by developing and commercializing therapeutics that modulate the innate immune system.

Share on Social Networks: